Subscribe to Newsletter
Diagnostics Genetics and epigenetics, Oncology, Biochemistry and molecular biology, Precision medicine

Hear both sides of the fusion detection story

sponsored by Thermo Fisher Scientific

Available On-Demand

March 26, 2020
4pm GMT / 12pm EDT / 9am PDT

Fusion based biomarkers are becoming more and more important in precision oncology clinical research and there is an ongoing discussion regarding the best method for their detection. In this webinar we will concentrate on NGS. A lot has been said recently about the importance of novel fusion detection. But let's not forget that most fusions occurring in cancer involve the same driver genes and partners which are known. And those can be present in very low level, or the sample as such can be very limited in tumor content. Therefore, and this is the other side of the story, sensitivity and LOD are also important for fusion detection. And there very possibly other sides, such as ease of use, Turnaround time and bioinformatics pipeline…

Learning Objectives

  1. Review 3 different methods data in comparison study performed and presented by Dr Wei Song.  
  2. Hear about principle and first data generated by new FusionSync method by Dr. Philip Jermann.  
  3. Discuss all above with both experts.

Available On-Demand

Visit our Webinar Hub

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Application Notes
Evaluation of cell-free fetal DNA to determine fetal RhD status

| Contributed by Revvity

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Enabling Efficient, Cost-effective Sequencing of the Human Whole Exome

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine